We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





HORIBA Unveils New Compact Hematology Analyzers with Combined ESR and CBC/Diff

By LabMedica International staff writers
Posted on 31 Jul 2024

HORIBA (Kyoto, Japan) is attending this year's ADLM where the company is showcasing its newly launched compact hematology analyzers that offer combined testing for Erythrocyte Sedimentation Rate (ESR) and complete blood count (CBC)/differential (Diff). More...

HORIBA recently expanded its award-winning compact hematology instrument range with the launch of new models with ESR on board. At ADLM 2024, HORIBA is presenting the new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) which now offer combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds.

Visitors to HORIBA’s booth at ADLM 2024 can learn more about the company’s innovative CoRA (Correlated Rouleaux Analysis) technology that has been used to integrate ESR into its three new analyzers. Combining CBC and 5-population white blood cell differential with rapid ESR, calibrated to the Westergren reference method, on one compact analyzer reduces costs per test and turnaround times, and saves laboratory space. Both the Yumizen H550E and H500E models have been further enhanced by offering new connectivity possibilities for data management through HORIBA’s Yumizen P8000 middleware, along with Yumicare. This remote technical support tool enables secure connection to the instrument to monitor workload, reagent consumption, quality control, and instrument alarms.

Also featuring is the new Yumizen C230 benchtop chemistry analyzer for small-volume laboratories with advanced and user-friendly features. This compact integrated solution is designed with system simplicity for efficient performance and processes tests with disposable cuvettes, enabling efficient resource usage. Paired with high-quality POINTE reagents, the new Yumizen C230 provides reliable test results. In addition, HORIBA is showcasing the new Yumizen C240 chemistry analyzer which is designed with system simplicity for expedient and efficient performance. Ideal for mid-sized to small labs, the Yumizen C240 is a compact and cost-efficient analyzer offering full walk-away capabilities and advanced features such as a washing station and pre-warmed detergent water.

Related Links:
HORIBA


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.